NZ Launches Genomic Testing Pilot to Deliver Faster Cancer Diagnoses

New Zealand is taking a major step toward modernising its healthcare system with the launch of a two-year national genomic testing pilot, designed to deliver faster diagnoses for cancer and rare disease patients while reducing reliance on overseas laboratories.

Health Minister Simeon Brown today announced the initiative, describing it as a "significant milestone" that will bring cutting-edge genomic medicine closer to patients and clinicians.

Ending Delays: Bringing Life-Saving Tests Back Home

Currently, thousands of New Zealanders face long wait times as their genomic samples are sent overseas for analysis—a process that can delay treatment decisions and prolong uncertainty.

"Too many Kiwis are left waiting for answers because their tests are processed offshore," Brown said. "This pilot will bring testing home, reducing delays at one of the most critical moments in a patient's journey."

The programme aims to:

• Reduce turnaround times for cancer and rare disease diagnoses

• Support faster clinical decision-making and treatment pathways

• Improve patient experience during high-stress periods

Processing 6,000+ Tests Locally

The pilot will significantly expand domestic capacity, with plans to process more than 6,000 genomic samples over two years—a notable increase compared to the 4,000+ tests currently sent overseas each year.

By the end of the trial:

• Around 50% of tests currently sent offshore are expected to be conducted within New Zealand

• New diagnostic workflows will be established and existing ones streamlined

This shift not only improves speed but also builds long-term resilience in the health system.

Advanced Technologies Through Global Partnership

Health New Zealand will partner with global genomics leader Illumina to deliver the pilot, providing access to state-of-the-art sequencing technologies while simultaneously developing local expertise.

The programme will deploy two key genomic approaches:

• Whole Genome Sequencing (WGS): Supporting diagnosis of rare and inherited conditions

• Comprehensive Genomic Profiling (CGP): Guiding cancer diagnosis and personalised treatment decisions

Together, these tools represent the forefront of precision medicine—tailoring care based on a patient's genetic profile.

Targeting Rare Disorders Across Multiple Conditions

The pilot will initially focus on a broad range of rare disorders, including:

• Metabolic diseases

• Connective tissue disorders

• Vision and hearing conditions

• Kidney (renal) disorders

Work is ongoing to determine priority cancer types for genomic profiling, with the aim of maximising clinical impact.

Building a National Genomics Service

Beyond immediate patient benefits, the initiative is designed as the foundation for a future national genomics service.

Key areas being evaluated include:

• Workforce capability in genomic medicine

• Operational efficiency and scalability

• Secure systems for managing sensitive genomic data

• Governance frameworks for ethical and safe data use

"This is not just about a pilot—it's about building the infrastructure and expertise for a world-class genomics service in New Zealand," Brown said.

Cost Savings and Data Sovereignty

The financial and strategic benefits are also significant.

New Zealand currently spends over $4 million annually sending genomic tests offshore. By shifting testing domestically:

• The system could save approximately $5 million over five years if scaled nationally

• Sensitive genetic data will be stored and managed within New Zealand, enhancing data security and sovereignty

Aligned with Rare Disorders Month

The announcement coincides with Rare Disorders Month, highlighting the urgency of timely diagnosis for thousands of New Zealanders living with complex conditions.

Delayed diagnosis—often referred to as the "diagnostic odyssey"—can take years for rare disease patients. Faster genomic testing has the potential to dramatically shorten this journey.

Patient-Centred Healthcare Transformation

The pilot reflects a broader shift toward precision, patient-centred healthcare, where early diagnosis and personalised treatment are prioritised.

"Our focus is on putting patients at the centre of the system," Brown said. "This initiative is about giving people answers sooner and ensuring they receive the right care at the right time."

If successful, the programme could redefine how New Zealand diagnoses and treats complex diseases—positioning the country at the forefront of genomic medicine in the region.